Back to search results

Apixaban Versus Warfarin for Left Ventricular Thrombus

This study is comparing two medications, apixaban and warfarin, to treat left ventricular thrombus (a blood clot in the heart's lower left chamber). Warfarin has been used for a long time but requires frequent blood tests and can be affected by food. Apixaban is a newer medication that doesn't require as many blood tests. We want to see if apixaban works just as well as warfarin to make the blood clot disappear. You might be able to join if you are 18 or older, have a confirmed left ventricular thrombus, and are able to take blood thinners for at least three months. The study aims to enroll 218 participants, but the current recruitment status is unclear.

Study design
This is a randomized study, meaning participants will be assigned by chance to receive either apixaban or warfarin. The study plans to enroll 218 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main goal is to see if the blood clot resolves at 3 months after you start treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07709780

Apixaban Versus Warfarin for Left Ventricular Thrombus

Recruiting
PHASE3Ages 18+InterventionalTreatment
University of Arizona
~218 participants
Updated 2026-07-17 on ClinicalTrials.gov
What's tested:ApixabanWarfarin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Complete Left Ventricular Thrombus Resolution at 3 Months
Measured over 3 months after randomization

Conditions

Left Ventricular Thrombus

Explore related trials

Left ventricular thrombusStrokeSystemic Embolism

NCT07709780

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Banner University Medical Center - Tucson

    Tucson, Arizonano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Tushar Acharya, MD, MPH
[email protected]
520-626-0968
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years
LV thrombus confirmed within 14 days prior to randomization by CMR or contrast TTE or cardiac CT; baseline CMR required pre-randomization (or ≤7 days post-randomization if clinically unavoidable)
Candidate for oral anticoagulation for ≥3 months
Able to provide informed consent.

Exclusion

Absolute indication for VKA (mechanical valve, moderate-severe rheumatic MS and antiphospholipid syndrome) or clear preference or contraindication for one of the study drugs precluding randomization (see below)
Antiphospholipid syndrome
Estimated CrCl \<15 mL/min or dialysis
Severe hepatic impairment (ICD-10: K70.40, K70.41, K71.10, K71.11, K72.00, K72.01, K72.10, K72.11, K72.90, K72.91)
Active clinically significant bleeding
Platelets \<50,000/µL
Pregnancy or lactation; women of childbearing potential unwilling to use contraception
Life expectancy \<1 year or other conditions compromising follow-up
Active pathological bleeding, major bleeding diathesis, or known blood dyscrasia
Recent or planned surgery involving the central nervous system or eye, traumatic surgery with large open surfaces, or procedures (spinal/epidural puncture or major regional block anesthesia) where bleeding cannot be safely controlled.
Conditions associated with high risk of bleeding such as threatened abortion, eclampsia, severe preeclampsia, or malignant/uncontrolled hypertension.
History of severe hypersensitivity or allergy to warfarin or apixaban.
Ongoing treatment with a combined P-gp and strong CYP3A4 inhibitor or inducer that cannot be safely discontinued or substituted. Examples include strong combined inhibitors such as ketoconazole, itraconazole, ritonavir or posiconazole, and strong combined inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort.

What this trial measures

  • Complete Left Ventricular Thrombus Resolution at 3 Months3 months after randomization

    Proportion of participants with complete resolution of left ventricular thrombus at 3 months, assessed by cardiac magnetic resonance imaging. The primary noninferiority comparison will use the absolute between-group difference in the proportion of participants with complete thrombus resolution, apixaban minus warfarin.